Three approved TTFields devices, $710M+ revenue guidance, but GBM expansion just failed — Optune Lua's brain-mets PMA is now the growth thesis

Bull

FDA approves the Optune Lua PMA for brain metastases from NSCLC based on the METIS Phase 3 data, establishing a new labeled indication in a high-prevalence CNS complication of the most common lung cancer. This would materially expand the patient funnel for Optune Lua, complement the existing metastatic NSCLC approvals, and re-establish a credible multi-indication growth trajectory following the GBM setback — potentially accelerating active patient growth well beyond the current 207 Optune Lua patients.

Bear

FDA issues a Complete Response Letter citing insufficient clinical benefit, the modest absolute OS or intracranial progression-free survival benefit observed in METIS, or device compliance concerns — mirroring the scrutiny applied to other TTFields submissions. A rejection or labeling restriction to a narrow subgroup would leave Optune Lua with limited incremental revenue opportunity beyond its current approved indications and would significantly damage confidence in the company's ability to expand TTFields into CNS indications following TRIDENT's failure.